Skip to main content

Table 4 Subjects with type 2 diabetes

From: Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor

Subjects

1

2

3

4

5

6

7

8

9

10

11

Baseline Glucose

117

173

323

321

113

110

254

261

137

386

457

Glucose after 1 month

51

187

137

135

133

106

186

118

334

138

Glucose after 6 months

164

167

158

107

97

143

116

77

HbA1c before

8.6

10

8.8

14.6

6

6.5

12.1

6.3

8.6

HbA1c after 1 month

5.2

7.5

11

6

6.7

HbA1c after 6 months

7.1

6.2

7.6

6.3

6

5.7

7.6

5.7

Treatment before

Glyburide

5 mg TID

Metformin 500 mg TID

Metformin 500 mg TID

Glyburide 5–5 – 2.5

Metformin / glyburide 500 mg/5 mg TID

Glyburide 5 mg BID

Metformin 850 mg QD

Metformin 500 mg QD

Metformin 500 mg QD

Glyburide 5 mg TID

Metformin 850 TID

Insulin Glargine 30 U QD

Metformin 850 mg QD

Metformin / glyburide 500 mg/5 mg half dose TID

NPH 45–0-20

Lispro 10–10-2

Glyburide 5 mg TID

Metformin 850 mg TID

Treatment after 6 months

Stayed the same

Metformin 500 mg TID

Glyburide 5 mg TID

Metformin /glyburide 500 mg/5 mg BID

Stayed the same

Stayed the same

NPH insulin 25 U QD

Metformin 850 mg TID

Stayed the same

NPH 25–0-20

Lispro 10–10-3

Suspended Metformin

Glyburide 5 mg TID

  1. HbA1c Glycated hemoglobin, TID three times a day, BID two times a day, QD once a day, NPH neutral protamine Hagedorn